DISCUSSION. EXTENSION OF TORSHAVN BREAKWATERS

Autor: Pa Cox, Clarke, N Rodda, Gm Morrey, Wa Price, Hl Wakeling, T Sorensen, S Langvad, June Palmer, Be Griffin, P Ackers, Dl Pope, Jw Hunter, Js Brindley

Publikováno v: Proceedings of the Institution of Civil Engineers. 58:87-93

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e13ae78366ce70a588d961984d52b7e
https://doi.org/10.1680/iicep.1975.3886

DISCUSSION. THE DEVELOPMENT OF LEITH HARBOUR. (INCLUDES CORRIGENDA)

Autor: Fe Prior, H. Scrutton, Re West, Pa Cox, Wj Leaman, A. Balfour Kinnear, D H Little, Jd Mettam, Dd Land, J Duvivier, J. Craig, Rw Bishop, Wr Miller, Jw Hunter, Rj Godden, Js Martin, Gm Cornfield, Dg Duff

Publikováno v: Proceedings of the Institution of Civil Engineers. 48:109-129

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::586b58bdc8b1224dfe19381a29dbb37a
https://doi.org/10.1680/iicep.1971.6482

DISCUSSION ON RAILWAY PAPER NO. 65: SITE AND LABORATORY WORK IN CONNEXION WITH THE DEVELOPMENT OF LONG WELDED RAIL TRACK ON THE WESTERN REGION OF BRITISH RAILWAYS

Autor: KD RHODES, MR DART, MGR SMITH, CE DUNTON, LGB ROCK, GDS ALLEY, CC INGLIS, AH CANTRELL, JW HUNTER

Publikováno v: Proceedings of the Institution of Civil Engineers. 7:364-376

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bfd27bbc060415804c6267f6ade47970
https://doi.org/10.1680/iicep.1957.2572

An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.

Autor: Davis AJ; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Brooijmans N; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Brubaker JD; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Stevison F; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., LaBranche TP; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Albayya F; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Fleming P; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Hodous BL; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Kim JL; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Kim S; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Lobbardi R; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Palmer M; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Sheets MP; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Vassiliadis J; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Wang R; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Williams BD; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Wilson D; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Xu L; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Zhu XJ; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Bouchard K; Alexion Pharmaceuticals, Boston, MA 02210, USA., Hunter JW; Alexion Pharmaceuticals, Boston, MA 02210, USA., Graul C; Invicro, Boston, MA 02210, USA., Greenblatt E; Invicro, Boston, MA 02210, USA., Hussein A; Invicro, Boston, MA 02210, USA., Lyon M; Invicro, Boston, MA 02210, USA., Russo J; Invicro, Boston, MA 02210, USA., Stewart R; Invicro, Boston, MA 02210, USA., Dorsch M; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Guzi TJ; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Kadambi V; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Lengauer C; Blueprint Medicines Corporation, Cambridge, MA 02139, USA., Garner AP; Blueprint Medicines Corporation, Cambridge, MA 02139, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2024 May 29; Vol. 16 (749), pp. eabp8334. Date of Electronic Publication: 2024 May 29.

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.

Autor: Lees-Shepard JB; Department of Molecular & Cell Biology, University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, Connecticut, USA., Stoessel SJ; Department of Molecular & Cell Biology, University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, Connecticut, USA., Chandler JT; Alexion Pharmaceuticals Inc., New Haven, Connecticut, USA., Bouchard K; Alexion Pharmaceuticals Inc., New Haven, Connecticut, USA., Bento P; Alexion Pharmaceuticals Inc., New Haven, Connecticut, USA., Apuzzo LN; Department of Molecular & Cell Biology, University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, Connecticut, USA., Devarakonda PM; Department of Molecular & Cell Biology, University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, Connecticut, USA., Hunter JW; Alexion Pharmaceuticals Inc., New Haven, Connecticut, USA., Goldhamer DJ; Department of Molecular & Cell Biology, University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, Connecticut, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2022 Jun 15; Vol. 132 (12).